{
  "id": 3941398,
  "title": "Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy",
  "url": "https://urgent.news/2026/08/28/teva-announces-proposed-acquisition-of-a-novel-neuroscience-product",
  "topic": "culture",
  "section": "Culture",
  "published": "2026-08-28T10:21:06.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/teva-announces-proposed-acquisition-of-a-novel-neuroscience-product-reinforcing-disciplined-business-development-approach-under-pivot-to-growth-strategy"
  },
  "original_language": "en",
  "account": null,
  "summary": "BXCL501, a novel dexmedetomidine sublingual film, is under FDA review for potential at-home (outpatient) use for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Agreement is part of a court-supervised sale process with BioXcel Therapeutics, Inc. and remains subject to bankruptcy court approval, potential higher bids, and customary closing…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}